heXembio

Rejuvenating Human Blood Cells for Improved Healthspan

Operating in therapeutics based in United States, heXembio was founded in 2024.

Profile

HexemBio is pioneering the world’s first blood stem cell rejuvenation therapy, a breakthrough platform emerging from >15 Millions from NIH. The company has raised $7.5 million in Seed funding and recently held a successful FDA Pre-IND meeting in January 2026 after being granted Orphan Drug Designation. Its technology, published in Nature, has been featured in The New York Times. The founding team includes 2 MDs, 2 PhDs, and 1 MBA from MIT, Harvard, UC Berkeley, Mayo Clinic, and Boehringer Ingelheim – second-time founders, Y Combinator alumni, and recipients of DARPA, NIH, and U.S. Presidential awards. HexemBio is backed by Draper VC, SOSV, Seraphim VC, Venture Science, Zentynel, Zaka VC, Innovation Works, Gaingels, Treeo VC, NY Venture. Its advisory includes Robert Langer (Moderna co-founder), Peter Barton Hutt (Moderna board), Joanne Kurtzberg, MD (leading U.S. clinician), David Harris, PhD (founder, first U.S. blood bank), Jens Nielsen, PhD (CEO, BII – $3B Novo Nordisk), and Felipe Sierra, PhD (former Director, Division of Aging, NIA/NIH).

As a business in therapeutics, heXembio is listed here with the public details available about it.

The business is associated with United States.

Directory data places it at the SOSV portfolio company stage.

Its team size is recorded as 2-10 employees.

Website: www.hexemb.io